Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release

J Control Release. 2005 Jul 20;105(3):344-53. doi: 10.1016/j.jconrel.2005.03.020.

Abstract

Therapeutic agents based on DNA or RNA oligonucleotides (e.g., antisense DNA oligonucleotide, small interfering RNA) require a regulation of their kinetics in cytoplasm to maintain an optimal concentration during the treatment period. In this respect, delivery of functional nanoparticles containing these drugs into cytoplasm has been thought to have a potential for the cytosolic controlled gene release. In this study, we establish a protocol for the encapsulation of nanoparticles into liposome, which is further fused with ultra violet-inactivated Sendai virus to compose fusogenic liposomes. When nanoparticles were encapsulated in conventional liposomes, endocytosis-mediated uptake of nanoparticles was observed. In contrast, numerous amounts of nanoparticles were delivered into the cytoplasm without any cytotoxicity when the particles were encapsulated in fusogenic liposomes. Additionally, fusogenic liposome showed a high ability to deliver nanoparticles containing DNA oligonucleotides into cytoplasm. These results indicate that this combinatorial nanotechnology using fusogenic liposome and nanoparticle is a valuable system for regulating the intracellular pharmacokinetics of gene-based drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cytosol / metabolism*
  • Drug Carriers
  • Drug Compounding
  • Excipients
  • Flow Cytometry
  • Genetic Therapy / methods*
  • Genetic Vectors
  • LLC-PK1 Cells
  • Liposomes*
  • Microscopy, Confocal
  • Microscopy, Electron, Transmission
  • Oligonucleotides / administration & dosage
  • Oligonucleotides / pharmacokinetics
  • Polyvinyl Chloride
  • Sendai virus / genetics
  • Swine

Substances

  • Drug Carriers
  • Excipients
  • Liposomes
  • Oligonucleotides
  • Polyvinyl Chloride